Related references
Note: Only part of the references are listed.A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies
Carlos Graux et al.
LEUKEMIA RESEARCH (2013)
Specifications of a continual reassessment method design for phase I trials of combined drugs
Nolan A. Wages et al.
PHARMACEUTICAL STATISTICS (2013)
Continual Reassessment Method for Partial Ordering
Nolan A. Wages et al.
BIOMETRICS (2011)
Dose-finding design for multi-drug combinations
Nolan A. Wages et al.
CLINICAL TRIALS (2011)
Maintenance Therapy With Low-Dose Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for Recurrent Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Marcos de Lima et al.
CANCER (2010)
Model calibration in the continual reassessment method
Shing M. Lee et al.
CLINICAL TRIALS (2009)
Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation
Yisheng Li et al.
STATISTICS IN MEDICINE (2008)
Simultaneously optimizing dose and schedule of a new cytotoxic agent
Thomas M. Braun et al.
CLINICAL TRIALS (2007)
Determining a maximum-tolerated schedule of a cytotoxic agent
TM Braun et al.
BIOMETRICS (2005)
Design efficiency in dose finding studies
X Paoletti et al.
COMPUTATIONAL STATISTICS & DATA ANALYSIS (2004)
Share Paper
